Market Research Logo

Polycystic Kidney Disease - Pipeline Review, H1 2015

Polycystic Kidney Disease - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Polycystic Kidney Disease - Pipeline Review, H1 2015’, provides an overview of the Polycystic Kidney Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Polycystic Kidney Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Polycystic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Polycystic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Polycystic Kidney Disease Overview
Therapeutics Development
Pipeline Products for Polycystic Kidney Disease - Overview
Pipeline Products for Polycystic Kidney Disease - Comparative Analysis
Polycystic Kidney Disease - Therapeutics under Development by Companies
Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes
Polycystic Kidney Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Polycystic Kidney Disease - Products under Development by Companies
Polycystic Kidney Disease - Products under Investigation by Universities/Institutes
Polycystic Kidney Disease - Companies Involved in Therapeutics Development
DiscoveryBiomed, Inc.
Endocyte, Inc.
IC-MedTech, Inc.
Ipsen S.A.
Kadmon Corporation, LLC
Metabolic Solutions Development Company, LLC
Otsuka Holdings Co., Ltd.
Synta Pharmaceuticals Corp.
Polycystic Kidney Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(ascorbic acid + menadione) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DBM-43H11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EC-0371 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JP-153 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MSDC-0160 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MSDC-0602 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STA-2842 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tesevatinib tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tolvaptan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polycystic Kidney Disease - Recent Pipeline Updates
Polycystic Kidney Disease - Dormant Projects
Polycystic Kidney Disease - Discontinued Products
Polycystic Kidney Disease - Product Development Milestones
Featured News & Press Releases
May 28, 2015: Otsuka’s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease
Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide
Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease
Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease
May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease
Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease
Dec 27, 2013: European Medicines Agency Accepts Otsuka's Marketing Authorisation Application for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Polycystic Kidney Disease, H1 2015
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed, Inc., H1 2015
Polycystic Kidney Disease - Pipeline by Endocyte, Inc., H1 2015
Polycystic Kidney Disease - Pipeline by IC-MedTech, Inc., H1 2015
Polycystic Kidney Disease - Pipeline by Ipsen S.A., H1 2015
Polycystic Kidney Disease - Pipeline by Kadmon Corporation, LLC, H1 2015
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company, LLC, H1 2015
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Polycystic Kidney Disease - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Polycystic Kidney Disease Therapeutics - Recent Pipeline Updates, H1 2015
Polycystic Kidney Disease - Dormant Projects, H1 2015
Polycystic Kidney Disease - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Polycystic Kidney Disease, H1 2015
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report